Regeneron Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
Sorry about that for everyone who is viewing -- who is in the Regeneron session. So my name is Evan Seigerman. I'm the senior biopharma analyst here at Crédit Suisse. And welcome to Day 1 of our Virtual Health Care Conference. I really wish we're all in Scottsdale together as that would be a lot more fun, and a little easier, given some technical difficulties this morning.
But it's my pleasure to have Marion McCourt and Justin Holko from Regeneron. I'm really excited to just have a fantastic conversation about everything that's happening at Regeneron from the COVID-19 antibody cocktail, EYLEA, Dupixent and the oncology franchise.
And before we jump into Q&A, I just want to pass it over to Justin for a quick disclaimer statement. And then Marion, I want to give you the floor for a quick introduction.
Sure. Thank you. Actually 2 disclaimer statements. The
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |